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Bacteroides fragilis has previously been linked to Crohn’s disease (CD) exacerbations,
but results are inconsistent and underlying mechanisms unknown. This study
investigates the epidemiology of B. fragilis and its virulence factors bft (enterotoxin)
and ubiquitin among 181 CD patients and the impact on the intestinal epithelial barrier
in vitro. The prevalence of B. fragilis was significantly higher in active (n = 69/88, 78.4%)
as compared to remissive (n = 58/93, 62.4%, p = 0.018) CD patients. Moreover,
B. fragilis was associated with intestinal strictures. Interestingly, the intestinal barrier
function, as examined by transepithelial electrical resistance (TEER) measurements of
Caco-2 monolayers, increased when exposed to secretomes of bft-positive (bft-1 and
bft-2 isotype; increased TEER∼160%, p < 0.001) but not when exposed to bft-negative
strains. Whole metagenome sequencing and metabolomics, respectively, identified nine
coding sequences and two metabolites that discriminated TEER-increasing from non-
TEER-increasing strains. This study revealed a higher B. fragilis prevalence during
exacerbation. Surprisingly, bft-positive secretomes increased epithelial resistance, but
we excluded Bft as the likely causative factor.
Keywords: Bacteroides fragilis, Crohn’s disease, barrier function, prevalence, metabolomics, whole genome
sequencing, organoids
INTRODUCTION
Crohn’s disease (CD) is a chronic inflammatory disease, characterized by patchy inflammation of
the intestinal mucosa with or without extra-intestinal manifestations (Baumgart and Sandborn,
2012). The disease course varies largely among patients with alternating periods of remission and
exacerbations. Insufficient control of the recurrent mucosal inflammation results in phenotype
progression and complications, such as strictures or fistulas, contributing to a high disease and
economic burden (Solberg et al., 2007; Floyd et al., 2015).
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CD onset is considered to involve genetic predisposition,
environmental factors and an adverse immune reaction to the
host microbiota (Baumgart and Sandborn, 2012). However,
the factors influencing the occurrence of exacerbations,
complications and disease phenotype remain largely unclear.
In recent years, microbial dysbiosis gained increasing
attention as a factor contributing to exacerbations (Baumgart
and Sandborn, 2012; Tedjo et al., 2016). Several studies
reported a decreased microbial diversity and altered microbial
composition in active CD patients compared to remission
(Prosberg et al., 2016; Tedjo et al., 2016; Galazzo et al., 2019).
As a consequence of compositional changes, alterations in overall
microbial functionality are conceivable (Li et al., 2020). Since
the intestinal epithelium limits bacterial attachment by a mucus
layer, bacteria often interact with the host via their secretome,
consisting of metabolites, proteins and bacterial membrane
vesicles (MVs) (Kaparakis-Liaskos and Ferrero, 2015; Sicard
et al., 2017; Parker et al., 2018; Caruana and Walper, 2020).
On the one hand, secreted glycosidases and mucinases have
been shown to degrade the mucus layer and allow microbes
to directly interact with epithelial cells (van Passel et al., 2011;
Sicard et al., 2017). On the other hand, bacterial metabolites,
such as the short chain fatty acid butyrate, have been reported
to promote mucus production and the sealing capacity of the
intercellular junctional complex (Sun et al., 2016; Zheng et al.,
2017). In CD, an impaired intestinal epithelial barrier function
has increasingly been recognized as a hallmark of exacerbations
(Baumgart and Sandborn, 2012). The impaired barrier function
has been associated with alterations in the epithelial junctional
complex (Zeissig et al., 2007; Lameris et al., 2013). It remains
unknown whether the observed altered microbiota composition
and functionality during CD exacerbations can contribute to this
impaired epithelial barrier.
In addition to alterations in microbial diversity, specific
microbial taxa were detected in CD exacerbations (Eeckhaut
et al., 2013; Schäffler et al., 2016; Tedjo et al., 2016) of
which Bacteroides fragilis is a prominent example (Wills et al.,
2014; Schäffler et al., 2016; Tedjo et al., 2016). Several studies
investigated the colonization of B. fragilis during exacerbation
and remission in fecal samples and biopsies. Together, the results
are inconclusive and based on rather low sample sizes (Scanlan
et al., 2006; Wills et al., 2014; Schäffler et al., 2016; Tedjo et al.,
2016). So far, it is still unclear whether the prevalence of B. fragilis
differs in different disease stages of CD and how it may affect
disease activity.
B. fragilis is a Gram-negative commensal of the phylum
Bacteroidetes and some strains secrete various virulence factors,
such as B. fragilis toxin (Bft; fragilysin) and an eukaryotic-like
ubiquitin (Ubb) (Sears, 2009; Stewart et al., 2018). It is yet unclear
whether these virulence factors contribute to CD exacerbations.
To gain more insights into the interaction between the
intestinal microbiota and the intestinal barrier in CD, especially
during dysbiosis, research essentially needs to focus on microbial
functionality, such as reflected by the secretome. In this study,
we therefore aim to investigate firstly the prevalence and relative
abundance of B. fragilis and virulence-factor positive strains
in a large, well-defined cross-sectional CD patient cohort and
secondly the impact of the B. fragilis secretome on the intestinal
epithelial barrier as first site of interaction and pathophysiological
factor in CD exacerbations. We hypothesize that B. fragilis and its
virulence factors bft and ubb are involved in exacerbations and by
disrupting the intestinal epithelial barrier.
MATERIALS AND METHODS
Patient Inclusion
Fecal samples of CD patients participating in the IBD South
Limburg (IBDSL) biobank project (van den Heuvel et al., 2015)
were available to evaluate the colonization of B. fragilis and
relevant strains in CD patients and the relation with disease
activity. Baseline characteristics, including medication use and
demographic information, were extracted from the IBDSL
database (van den Heuvel et al., 2015).
Patients with a fecal calprotectin level >200 µg/g were
defined as active (n = 88) and patients with a fecal calprotectin
level <100 µg/g as remissive (n = 93). Remissive patients
without previously reported calprotectin level >200 µg/g were
excluded to avoid misclassification unless the previously elevated
calprotectin level was combined with a CRP value <10 mg/l.
In addition, from two patients having a colonoscopy
scheduled for clinical reasons, biopsies were collected from the
macroscopically non-inflamed tissue of the ascending colon for
crypt isolation and subsequent organoid culture (Xu et al., 2018).
All patients participated in the IBDSL cohort and gave written
informed consent prior to sample collection. The study protocol
was approved by the Medical Ethics Committee of the Maastricht
University Medical Centre+ (NL31636.068.10) and registered on
www.clinicaltrials.gov (NCT02130349).
Fecal DNA Isolation
Fecal samples stored at –80◦C within 24 h after collection were
obtained from the IBDSL biobank (van den Heuvel et al., 2015)
and cut frozen to obtain ∼0.5 g feces. DNA isolation was
conducted using Qiagen QIAamp DNA mini kit (Qiagen, ref.:
51306) according to protocol Q of the International Human
Microbiome Standards consortium (Costea et al., 2017) with
minor adjustments in FastprepTM cycles (three series of 1 min of
beating at 5.5 ms and 1 min resting) and vacuum drying at 37◦C
for 7 min instead of 3 min. Eluted DNA was stored in Buffer AE
(Qiagen) at –20◦C until further analysis.
Enumeration of Fecal B. fragilis
Metagenomic DNA obtained from the fecal samples was analyzed
for the presence and relative abundance of B. fragilis as well
as the virulence factors bft and ubb by means of real-time
quantitative PCR. Samples containing B. fragilis specific gyrB
were subsequently analyzed for the presence of bft and ubb.
The PCR mix for gyrB and bft contained 5 µl DNA,
12.5 µl Absolute quantitative PCR mix (Abgene, Epsom,
United Kingdom), 500 mM forward and reverse primer (Sigma-
Aldrich; Supplementary Table 1), 250 nM probe and was
supplemented with DNAse-free water to a final volume of 25 µl.
qPCR and analysis were conducted with 7900HT Fast Real-Time
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PCR System (Applied Biosystems) and SDS 2.3 software (Applied
Biosystems). PCR cycles for gyrB and bft were 2 min at 50◦C,
10 min at 95◦C, followed by 42 amplification cycles of 15 s at 95◦C
and 60 s at 60◦C.
PCR mix for ubb and 16S rRNA contained 2 µl DNA, 12.5 µl
Absolute qPCR SYBR Green supermix (Bio-Rad, Hercules,
CA), 300 nM forward and reverse primer (Sigma-Aldrich;
Supplementary Table 1) and was supplemented with DNAse-
free water to a final volume of 25 µl. qPCR and analysis were
conducted with MyIQ Single Color Real-Time PCR Detection
System (BioRad) and iQ5 software (BioRad). PCR cycles for ubb
and 16S rRNA were 3 min at 95◦C, followed by 40, respectively,
35 amplification cycles of 95◦C, 20 s at 63◦C, respectively, 55◦C,
and 30 s at 72◦C. The melting curve was assessed in 60 cycles of
0.5◦C for 10 s each.
B. fragilis Isolation From Fecal Samples
To retrieve toxigenic and non-toxigenic B. fragilis strains for
in vitro experiments, a random selection of fecal samples of three
CD patients and two samples of healthy controls (HC) from a
previous study that were positive for B. fragilis specific gyrB were
cultured. A portion of∼1 g was dissolved in Brain Heart Infusion
broth (BHI; Sigma Millipore, ref.: 53285, Darmstadt, Germany)
containing 4 µg/ml Vancomycin hydrochloride (No 15327,
Cayman Chemical, Michigan, United States) and incubated in
an anaerobic jar (80% N2, 10% CO2, 20% H2) at 37◦C for
24 h. Next, 1:100 dilutions were inoculated on Bacteroides Bile
Esculin Agar with Amikacin (Becton Dickinson, ref.: 254480,
Landsmeer, Netherlands) and incubated for 48 h under the
same conditions. Medium to large sized single colonies were
subsequently inoculated on Columbia Agar with 5% Sheep Blood
(Becton Dickinson, ref.: 254005, Landsmeer, Netherlands) and
incubated for 48 h, as described before. This was repeated to
guarantee pure cultures. A single colony was then collected in
DNAse-free water and checked for gyrB, bft and ubb using qPCR
as described above. The PCR products of bft and ubb were
confirmed using Sanger sequencing to avoid false positive results.
Amplicons were purified from remaining nucleotides using the
MSB Spin PCRapace-kit (Stratec molecular, ref.: 1020220400)
according to manufacturer’s descriptions. One microliter of DNA
was then added to 5.5 µl DNAse-free water, 1 µl forward or
reverse primer (2 pmol/l), 1.5 µl BDT 1.1 buffer and 1 µl BDT
v1.1 enzyme mix. The DNA was amplified with one cycle of 1 min
at 96◦C and 22 cycles of 10 s at 96◦C, 5 s at 58◦C and 2–3 min
at 60◦C. Subsequently, the amplicons were sequenced using an
ABI 3730 DNA Analyzer (Thermo Fisher Scientific) and were
compared to the Nucleotide Basic Local Alignment Search Tool
(BLAST; NCBI) database for sequence similarity with previously
sequenced B. fragilis derived bft and ubb.
In total, five B. fragilis strains were isolated. As no ubb-positive,
bft-negative genotype was identified, a reference strain from
the American Type Culture Collection (ATCC R© 25285TM) was
obtained. Two further reference strains were kindly provided by
prof. Sears (John Hopkins University, Baltimore, United States),
namely bft-1-positive VPI 18786 (VPI) and bft-2-positive 86-
5443-2-2 (086) and their respective bft deletion mutants (VPI
1bft, 086 1bft) (Myers et al., 1984; Myers and Schoop, 1987;
Rhee et al., 2009; Chung et al., 2018). Finally, the following
strains were available for further analysis: one ubb-positive
strain (ATCC R© 25285TM), two bft-positive strains (CD-2, CD-
3), one strain positive for both bft and ubb (HC-1), two strains
negative for both virulence factors (HC-2, CD-1; Supplementary
Table 2), one bft-1-positive strain (VPI) with corresponding
deletion mutant (VPI 1bft), and one bft-2-positive strain (086)
with corresponding deletion mutant (086 1bft).
B. fragilis Supernatant
To study the impact of excreted B. fragilis products on the
intestinal barrier in vitro, bacterial culture supernatant was
used. Therefore, three to five colonies of B. fragilis strains were
inoculated in BHI (Sigma Millipore, ref.: 53285) for 24 h at
37◦C in anaerobic jars. Subsequently, bacterial cultures were
centrifuged at 4,500 × g for 15 min at 4◦C and supernatant was
filtered through 0.2 µm pore size syringe filters (Pall Life Sciences,
ref: 4652). To increase the sensitivity, filtered supernatant was
concentrated 20× using Amicon R© Centrifugal Units 10 K (Merck
Millipore, ref.: UFC8010) at 4,000 × g for 20 min. Cell-free
supernatant was stored at 4◦C and used for transepithelial
electrical resistance (TEER) experiments within 24 h.
B. fragilis MVs
To investigate the impact of MVs on intestinal epithelial
barrier function we separated the MVs from the B. fragilis
cell-free supernatant. First, 30 ml of supernatant (see above)
was concentrated to ∼250 µl during several centrifugation
steps at 4,000 × g at 4◦C using Ultracentrifugal Filters of
100 kDa (Merck Millipore, ref: UFC9100). After collection of the
concentrate, the filter was washed with 250 µl PBS to recover
the remaining particles. MVs were isolated by Size Exclusion
Chromatography using CL-2B Sepharose (GE healthcare, Little
Chalfont, United Kingdom). As described by Benedikter et al.
(2017) vesicle-rich fractions were pooled and the concentration
was determined by tunable resistive pulse sensing using qNano
Gold (Izon Science Ltd., Oxford, United Kingdom) and Izon
Control Suite software v3.2.
Bft Secretion and Activity
To examine the presence of Bft in the cell-free B. fragilis
supernatant, we isolated the total protein fraction following the
protocol of Casterline et al. (2017) with minor modifications. One
milliliter of culture supernatant was precipitated with 10% (v/v)
trichloric acid in acetone containing 20 mM 1,4-dithiothreitol
(DTT) for 1 h on ice and centrifuged at 15,000 × g for 15 min.
The pellet was washed twice with acetone, carefully resuspended
and centrifuged at full speed for 15 min. The pellet was then
recovered in 2× Laemmli buffer, containing 4% SDS, 10% 2-
mercaptoethanol, 20% glycerol, 0.004% bromophenol blue and
0.125 M Tris-HCl, and stored at –20◦C. For subsequent western
blot analysis, the samples were further denatured at 95◦C for
10 min and loaded on a 13% SDS gel according to standard
protocol. After separation and wet blotting on an AmershamTM
ProtranTM 0.2 µm nitrocellulose membrane (GE Healthcare),
the membrane was blocked with skim milk in TBST for 1 h at
RT. The membrane was then incubated with anti-Bft antibody
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(Cusabio, ref.: CSB-PA346537LA01BDP) diluted 1:2,000 for 36 h
at 4◦C, followed by goat-anti-rabbit antibody conjugated with
horseradish peroxidase (Dako p0448) diluted 1:2,000 for 30 min
at RT and developed with 0.1 M Tris pH 7.5, 0.2 mg/ml DAB,
0.01% NiCl2 and 0.03% H2O2. Pictures were taken with Mini HD
9 (Uvitec, Cambridge, United Kingdom).
Bft activity was confirmed by a slightly adapted HT-29 cell
rounding assay (Weikel et al., 1992; Mundy and Sears, 1996).
In brief, HT-29 cells were cultured for 5 days in a 96-well plate
at a density of 2,000 cells/well with Dulbecco’s Modified Eagle
Medium (DMEM; Sigma Aldrich, ref.: D6429) supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Gibco, ref.
10500) and 1% antibiotic-antimycotic (100×; anti-anti; Gibco,
ref.: 15240-062). Cells were then washed thrice with PBS (Gibco,
Life Technologies, ref.: 10010-031) and incubated overnight with
20× concentrated B. fragilis cell-free supernatant diluted 1:10
in HT-29 culture medium without FBS at 37◦C. Cell rounding
was examined by confocal light microscopy (Leica Microsystems
GmbH, Mannheim, Germany), images were taken using LAS-
AF software (Leica Microsystems) and analyzed using ImageJ
(Abràmoff et al., 2004).
Barrier Function Analysis
Caco-2 cell monolayers (passage number 47–57), as a well-
established in vitro model for intestinal epithelial barrier function
(Srinivasan et al., 2015), were seeded on Millicell Hanging Cell
Culture Inserts (Merck Millipore, ref.: MCHT24H48) at a density
of 100,000 cells/insert in DMEM supplemented with 1% FBS,
0.1% non-essential amino acids (Gibco, ref.: 11140050) and 0.1%
anti-anti. Culture medium was refreshed every 2–3 days in
both compartments. Monolayers were allowed to differentiate
during 14–21 days at 37◦C and 5% CO2 and the TEER was
evaluated using the EVOM2 Epithelial Volt/Ohm Meter (World
Precision Instruments, Sarasota, FL, United States). Mature
monolayers (TEER > 600 ∗cm2) were luminally exposed to
BHI or bacterial-free concentrated culture supernatant, each
diluted 1:10 in Caco-2 culture medium, or to PBS or a final
concentration of 5× 107 MVs in PBS, each diluted 1:2 in Caco-2
culture medium, and incubated for 24 h. To investigate whether
B. fragilis supernatant is able to prevent cytokine induced barrier
disruption, experimental conditions were pre-incubated basally
with 100 ng/ml tumor necrosis factor α (TNF-α; Sigma, ref.:
T6674) in combination with 100 ng/ml interferon γ (IFN-γ;
Sigma, ref.: I3265) for 1 h, before B. fragilis supernatant was added
luminally. After another 24 h of co-incubation, TEER values
were assessed and expressed as percentage of the TEER value
prior to incubation.
To confirm that relevant findings were not restricted to Caco-
2 cells, concentrated B. fragilis culture supernatant was also
applied to the more physiological model of colonic patient-
derived organoids. Therefore, colonic biopsies were collected in
cold PBS, washed thrice with 1% anti-anti in PBS, thrice with
10 mM DTT in PBS and incubated with 2 mM EDTA in PBS
for 1 h at 4◦C and 5 rpm. Biopsies were transferred to PBS and
crypts were separated by several rounds of mechanical shaking.
The pooled crypt supernatant was then supplemented with 5%
FBS and centrifuged at 400 × g for 8 min at 4◦C. The pellet
was washed twice with 2 ml cold basal medium (DMEM/F12;
Gibco, ref.: 12634-010) supplemented with 1% GlutaMaxTM (Life
Technologies), 1% Hepes buffer (Life Technologies) and 5% FBS.
After centrifugation at 400 × g for 3 min, crypts were plated in
GelTrexTM (Gibco, ref: A1413201) and IntestiCultTM Organoid
Growth Medium (StemCell Technology GmbH, Germany, ref.:
SC-06010) was added 15 min after incubation at 37◦C, 5%
CO2. Medium was refreshed every 3 days and passaged when
the morphology appeared complex, according to previous
descriptions (Sato et al., 2011). In brief, GelTrexTM with
enclosed organoids was solubilized on ice for 15 min. Culture
medium was replaced by ice cold basal medium. Organoids were
disrupted mechanically using a 1000P pipette and centrifuged at
150 × g for 5 min. The supernatant was replaced by TrypLETM
Express (Thermofisher Scientific, ref: 12605010) containing
10 µM y27632 (Tebu-bio BV) and incubated at 37◦C for
2 min. Organoids were then dissociated mechanically using a
firepolished Pasteur pipetted, washed and centrifuged twice with
basal culture medium at 400× g for 5 min. Finally, the pellet was
resuspended with GelTrexTM and cultured as described above.
Single lumen organoids (passage numbers 10 and 11)
were incubated basolaterally with BHI or B. fragilis culture
supernatant, diluted 1:10 in organoid medium, or organoid
medium only at 37◦C for 24 h. Epithelial barrier function
was evaluated by 1 mg/ml fluorescein isothothiocyanate-
labeled dextran of 4 kDa (FITC-d4; Sigma) added 6–8 h
before confocal light microscopy (Leica Microsystems GmbH,
Mannheim, Germany). Images were taken using LAS-AF
software and processed using ImageJ. The experiment was
conducted twice and at least eight organoids were evaluated per
condition and experiment.
Analysis of Tight- and Adherens Junction
Expression
After TEER measurements of Caco-2 monolayers, RNA
was isolated using RNeasy Mini Kit (Qiagen) according to
manufacturer’s instructions, including DNAse treatment for
15 min. RNA quantity and purity were determined using
a Nanodrop spectrophotometer (NanoDrop Technologies,
Wilmington, United States). cDNA was synthesized using
75% RNA template, 20% iScript reaction mix and 5% reverse
transcriptase (by iScript cDNA Syntgeses Kit BioRad) and the
recommended cycle of 5 min 25◦C, 30 min 42◦C and 5 min 85◦C.
Real-time qPCR was performed according to manufacturer’s
instructions using SYBR Green Supermix (BioRad, Veenendal,
Netherlands, ref.: 1708885) and CFX 96 Real Time System C1000
Touch Thermal Cycler (Bio-Rad). Primer sequences are listed
in Supplementary Table 3. Expression of mRNA was analyzed
relative to GAPDH, using the 2−1Ct method (Schmittgen and
Livak, 2008).
Analysis of Tight Junction Localization
After TEER measurements of Caco-2 monolayers, the cells were
washed with PBS, fixated with 4% (w/v) paraformaldehyde as
described previously (Elamin et al., 2012). The protocol was
adjusted by 30 min permeabilization with 0.5% (v/v) Triton
X-100 and washing with PBS instead of Hank’s balanced salt
solution. Monolayers inside the transwells were incubated with
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FITC-conjugated Zonulin-1 antibodies (1:200; Invitrogen, ref.:
339111) overnight at 4◦C. Confocal images were obtained as
described in section “Barrier Function Analysis.”
Whole Genome Sequencing
To characterize the isolated B. fragilis strains and to predict
possible differences in secreted proteins, the genome of all six
strains was sequenced. Genomic DNA was isolated from single
colonies resuspended in PBS using MasterPureTM Complete
DNA and RNA purification kit (Epicenter, MC 85200), following
the manufacturer’s protocol. Library preparation sequencing and
de novo assembly was performed as described previously (Flipse
et al., 2019). Coding sequences were annotated using Prokka
(v1.7) (Seemann, 2014). Gene presence/absence was determined
using Roary (v3.11.2) (Page et al., 2015). SNP distances among
isolates was determined using SKA (v1.0) (Harris, 2018). All
bioinformatics tools were run in default settings. Sequencing
data are deposited at European Nucelotide Archive (ENA) with
accession number PRJEB41450.
Metabolite Identification Using NMR
Spectroscopy
To further examine potential differences in excreted metabolites
by the different B. fragilis strains, the culture supernatants
were analyzed using proton (1H) NMR spectroscopy. Therefore,
150 µl of 20× concentrated B. fragilis culture supernatant was
diluted in 420 µl 100 mM phosphate buffer (pH 7.4 at 25◦C) and
30 µl Deuterium oxide (D2O, 99 atom%D, 100G, Sigma-Aldrich,
Germany) containing 1 mM 3-(trimethylsilyl)propiomic-2,2,3,3-
d4 acid (TSP, 98 atom%D TSP, 1G, Sigma-Aldrich, Germany).
The samples were then transferred into a 5 mm NMR tube
(Bruker samplejet, Sigma-Aldrich, Germany). All 1H NMR
spectra were recorded on a 700 MHz Bruker Avance spectrometer
(Bruker, Germany) at 300 K. Spectra were acquired using a
one-dimensional NOESY-presat pulse sequence (RD-90◦-t-90◦-
tm-90◦-ACQ), an acquisition time of 2 s, a relaxation delay (D1)
of 5 s, mixing time (D8) of 100 ms, receiver gain of 32, 64 scans,
45 K data points and a spectral width of 11,161 Hz (15.934 ppm).
Spectral preprocessing and preliminary comparisons of the
spectra were performed using the Bruker TopSpin 3.2 software.
Statistical Analyses
In order to compare the prevalence and relative abundance of
B. fragilis (virulence factors) in active and remissive CD patients’
samples, the χ2-test with Yate’s correction and Wilcoxson rank
sum test (for samples tested positive for the respective gene)
were performed. To predict carriage of B. fragilis, based on
the combination of patient baseline characteristics (age, gender,
Montreal classification, and medication use), multivariate logistic
regression was conducted using backward stepwise regression
based on the likelihood ratio. Analyses were computed in IBM
SPSS Statistics 25 and statistical significance was considered when
p < 0.05.
Comparing the effects of B. fragilis supernatant and MVs on
TEER of Caco-2 epithelial monolayers one-way ANOVA and
Tukey’s post hoc test was performed using GraphPad Prism 5. For
subsequent analysis of differences in tight junction expression,
student’s t-test was applied. Statistical significance was considered
when p < 0.05. Analyses were based on at least duplicate
experiments with each three technical replicates.
Partial Least Squares Discriminant Analysis (PLS-DA) was
conducted to identify biologically relevant metabolites that differ
between TEER-increasing and non-TEER-increasing groups
using MetaboAnalyst v2.0 (Chong et al., 2019). The selection
of the most discriminating metabolites, that are responsible for
the pattern of the PLS-DA score plot, was based on both the
interpretation of PLS-loading plot and Variable Importance in
Projection (VIP) scores. Metabolites were identified using HMDB
4.0 (The Human Metabolome Database) (Wishart et al., 2018).
RESULTS
Patient Population
In total, 181 CD patients, 88 with active disease and 93 in
remission, from the IBDSL (van den Heuvel et al., 2015) cohort
fulfilling the inclusion criteria were available for the present
study. Baseline characteristics were comparable between patient
groups, although steroid use was slightly higher among patients
with active disease (Table 1).
B. fragilis Prevalence and Relative
Abundance
Based on the detection of the B. fragilis specific gyrB gene,
the prevalence of B. fragilis was significantly higher among CD
patients during an exacerbation (78.4%) when compared to those
in remission (62.4%, p = 0.018, Figure 1A). We subsequently
determined the prevalence of the B. fragilis virulence factors bft
TABLE 1 | Baseline characteristics of the CD patient cohort.
CD remission (n = 93) CD exacerbation (n = 88)
Age (median in
years; IQR)
43.0 (32.0–56.5) 45.0 (28.0–57.0)
Gender (% female) 63.4 51.1
Calprotectin
(median; IQR)
22.0 (14.0–55.5) 476.5 (325.8–703.0)
Montreal
classification (%)
A1; A2; A3 6.5; 67.7; 25.8 10.2; 61.4; 28.4
L1; L2; L3; L4 35.5; 17.2; 47.3; 4.3 23.9; 21.6; 54.5; 11.4








L1, terminal ileum; L2, colon; L3, ileocolon; A1, <16 years, A2, 17–40 years,
A3, >40 years at diagnosis; B1, without stricture formation, non-penetrating; B2,
stricturing; B3, penetrating.
Frontiers in Microbiology | www.frontiersin.org 5 June 2021 | Volume 12 | Article 598232
fmicb-12-598232 June 2, 2021 Time: 17:58 # 6
Becker et al. B. fragilis in Crohn’s Disease Exacerbations
FIGURE 1 | B. fragilis is more prevalent in CD exacerbation samples. (A) The prevalence of B. fragilis specific gyrB is 16.0% higher in active CD compared to
remission (*p = 0.018), while the prevalence of the virulence factors bft and ubb does not differ significantly between groups (p = 0.376 and p = 0.164, respectively).
The relative abundance of gyrB (B), bft (C), and ubb (D), based on 16S rRNA gene copy number, does not significantly differ between active CD and remission
(p = 0.837, p = 0.283 and p = 0.196, respectively).
and ubb. Only 11.4 and 7.5% (p = 0.376) of the samples from the
exacerbation and remission group, respectively, were positive for
bft. When considering only samples that were tested positive for
B. fragilis, this equals to a proportion of bft-positive samples of
14.5 and 12.1% (p = 0.689), respectively. For ubb, the prevalence
was 19.3 and 11.8% (p = 0.164) in the entire exacerbation and
remission group, respectively, and 24.6 and 19.0% (p = 0.442),
when considering the gyrB positive samples only (Figure 1A).
The relative abundance of gyrB, bft and ubb was not significantly
different between remission and exacerbation (Figures 1B–D).
Based on multivariable logistic regression, we found the
following patient characteristics to be correlated with overall
B. fragilis colonization: a stricturing disease behavior (Odds ratio
(OR) = 3.212, 95% CI = 1.218; 8.469, p = 0.018), active Crohn’s
disease (OR = 2.048, 95% CI = 1.042; 4.027 p = 0.038), and
previous intestinal resections (OR = 0.406, 95% CI = 0.194; 0.848,
p = 0.016).
B. fragilis Strain Isolation and
Characteristics
In order to examine the impact of B. fragilis and its virulence
factors on barrier function, we selected five B. fragilis strains
cultured from samples of two healthy controls (HC-1, HC-2)
and three CD patients (CD-1, CD-2, CD-3) and additionally
included one reference strain (ATCC R© 25285TM). Based on
whole genome sequencing, pairwise genetic distance revealed
only 160 SNPs between the CD-2 (bft-positive) and the CD-1
(bft-negative) strains, whereas the median distance was 16960
SNPs among all strains (Figure 2A). The genomic similarity
was 89.7%, based on shared split kmers between these two
strains using Jaccard dissimilarity (mean Jaccard index 59.9%).
This indicates a large shared genomic backbone in these two
strains. Sanger sequencing confirmed the presence of bft-1
in HC-1, CD-2, and CD-3 and the presence of ubb in HC-
1 and ATCC R© 25285TM with 93–99 and 96–99% sequence
similarity, respectively. HC-2, ATCC R© 25285TM, and CD-1 were
confirmed negative for bft, and HC-2, CD-1, CD-2, and CD-
3 for ubb. Cell rounding of subconfluent HT-29 cells could
be detected in response to the supernatants of all bft-positive
strains, which was interpreted as Bft activity (Figure 2B and
Supplementary Figure 1). No cell rounding was detected in
bft-negative strains, including both bft deletion mutants, which
supported the assay specificity. However, the concentration of
Bft was found to be below the detection limit of western blot
analysis (Figure 2C). In addition, no cell rounding was detected
when applying concentrated culture supernatant of bft-1 positive
strains (HC-1, CD-2, CD-3) on Caco-2 cells (data not shown)
or colonic organoids (CD-3; Figure 3E), which suggests a cell
type-dependent response to Bft. No cell rounding was detected
on bft-1 positive strains derived MVs, suggesting that the isolated
MVs do not contain or release relevant amounts of (active)
Bft (Figure 2D).
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FIGURE 2 | Characteristics of cultured B. fragilis strains. (A) Based on whole genome sequencing, pairwise genetic distance revealed 160 SNPs between CD-1 and
CD-2, whereas the median distance was 16960 SNPs. (B) Cell rounding of subconfluent HT-29 cells could be detected in the supernatants of all bft-positive strains
(HC-1, CD-2, CD-3). (C) Mature Bft could not be detected in the supernatant of bft-positive strains when compared to 200 ng of recombinant mature Bft (r-mBFT).
(D) Cell rounding of subconfluent HT-29 cells could not be detected in response to bft-positive strain-derived MVs.
Barrier Modulation by B. fragilis
Supernatant and MVs
After 24 h exposure to concentrated supernatant of bft-positive
strains, no decrease in TEER was detected. Instead, TEER values
increased up to 160% (p < 0.001) when compared to BHI control
and to the concentrated culture supernatant of naturally bft-
negative strains (Figure 3A). A similar increase by bft-positive
supernatant was also observed after 1 h basal pre-incubation
with 100 ng/ml TNF-α and 100 ng/ml IFN-γ (+cyt), while bft-
negative culture supernatant did not alter TEER (Figure 3B).
To examine the potential role of bft-1 in the observed TEER
increase, we applied the concentrated culture supernatant of a bft-
1-positive reference strain and its respective deletion mutant. In
addition, we examined whether the effect is isotype specific by the
additional inclusion of a bft-2 reference strain and its respective
deletion mutant.
For bft-1-positive VPI and bft-2-positive 086, as well as their
respective deletion mutants, a significant TEER increase was
detected (Figure 3C).
Besides culture supernatant, we also examined the effect
of MVs, which are vesicles released by Gram positive and
Gram negative bacteria and can deliver a variety of products,
including toxins, to host cells or neighboring bacteria (Brown
et al., 2015; Kaparakis-Liaskos and Ferrero, 2015; Caruana and
Walper, 2020). After 24 h incubation with 5 × 107 MVs/ml, no
alterations in TEER were observed in differentiated Caco-2 cell
monolayers (Figure 3D).
Using a more physiological patient-derived colonic organoid
model and a functional FITC-d4 permeation assay, we confirmed
that the supernatant of different B. fragilis strains did not disrupt
the epithelial barrier nor altered the morphology upon 24 h basal
incubation (Figure 3E).
Junctional Alterations in Response to
B. fragilis Supernatant
To further elucidate the mechanisms underlying the TEER
enhancing effect of Bft-positive culture supernatant, we
performed qPCR to analyze the mRNA expression of various
junctional genes and the proto-oncogene c-myc in Caco-2
cells. When comparing one bft-positive (CD-3) and one bft-
negative (CD-1) strain in quadruplicate, we could not detect
any significant alterations in gene expression levels of junctional
genes or c-myc (Figure 4 and Supplementary Figure 2).
When evaluating ZO-1 protein localization, no alterations were
observed comparing exposure to CD-1 and CD-3 supernatants
(Supplementary Figure 3).
Identification of B. fragilis Genome and
Metabolome
To identify potential bacterial proteins that may strengthen
the epithelial barrier, coding sequences of TEER-elevating
strains were compared to those of non-TEER-elevating
strains. Herein, nine proteins were identified which were
only present in TEER-elevating strains: Bft1, Metalloprotease II
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FIGURE 3 | Barrier function examination of Caco-2 monolayer and colonic organoids exposed to B. fragilis culture supernatant and MVs. (A) Luminally applied
B. fragilis concentrated culture supernatant of HC-1, CD-2, and CD-3 led to increased TEER after 24 h. (B) Pre-incubation with 100 ng/ml TNF-α and IFN-γ could
not impair the TEER enhancing effect of HC-1. (C) Luminally applied B. fragilis concentrated culture supernatant of 086, 086 1bft-2, VPI, and VPI 1bft-1 led to
increased TEER after for 24 h. (D) Luminally applied MVs, isolated from different B. fragilis strains, did not lead to TEER alterations in Caco-2 cell monolayers after
24 h. (E) CD patient-derived colonic organoids treated basally with B. fragilis CD-1 and CD-3 concentrated supernatant and FITC d4 (green) remain a stable barrier
after 24 h incubation. Means ± SD was based on triplicates of one representative experiment. cyt, cytokines; BHI, brain heart infusion broth. **p < 0.01,
***p < 0.001.
(MPII), putative amidoligase, transposase like protein, putative
transposase/insertion sequence protein, and four hypothetical
proteins (Table 2).
To further identify metabolites produced by the different
B. fragilis strains that might contribute to the observed
barrier enhancing effect, the concentrated culture supernatants
were analyzed using 1H Nuclear Magnetic Resonance (NMR)
spectroscopy. All strains show comparable metabolic profiles
(Figure 5A). Based on PLS-DA, the TEER-enhancing and non-
TEER-enhancing groups could be discriminated based on a
decreased relative concentration of acetate and lactate in the
TEER-enhancing group (Figure 5B).
DISCUSSION
Previously, B. fragilis colonization has been investigated in
CD exacerbations, together providing inconclusive results
(Prindiville et al., 2000; Wills et al., 2014; Schäffler et al., 2016;
Tedjo et al., 2016). Based on previous research, we hypothesized
that B. fragilis and its virulence factors bft and ubb are associated
with exacerbations and may contribute to exacerbations by
disruption of the intestinal epithelial barrier (Wells et al., 1996;
Chambers et al., 1997; Obiso et al., 1997; Wu et al., 1998;
Riegler et al., 1999).
In the present study, we indeed observed a higher B. fragilis
prevalence among active CD patients when compared to
patients in remission, but not in virulence factor-positive strains.
Furthermore, disruption of the intestinal epithelial barrier by
supernatant of various (non)virulent B. fragilis strains could
not be observed. Intriguingly, Bft-positive culture supernatant
even led to a significant increase of intestinal epithelial barrier
resistance in Caco-2 monolayers.
The cross-sectional investigation of B. fragilis in our
large CD cohort demonstrated a higher prevalence in active
CD patients. However, no differences in relative abundance
were detected when analyzing B. fragilis positive samples.
Logistic regression analysis confirmed the association between
B. fragilis colonization and disease activity and additionally
highlighted an increased likelihood of B. fragilis carriage
among patients with a stricturing disease behavior. To our
knowledge, an association with disease behavior has previously
not been reported. Previous research has shown that B. fragilis
lipopolysaccharide can activate Toll-like receptor 4, which in
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FIGURE 4 | Paracellular junction gene expression in Caco-2 cells exposed to B. fragilis culture supernatants remains unaltered. Tight junction (Claudins, ZO-1,
Occludin), adherens junction (E-cadherin, beta-catenin) and tricellulin gene expression were unaltered in B. fragilis bft-positive CD-3 compared to bft-negative CD-1
culture supernatant. Means ± SD were based on two independent experiments. ZO-1, Zonulin 1.
turn has been associated with liver fibrosis and was suggested
as a potential mechanism in stricturing CD (Mancuso et al.,
2005; Li et al., 2019). This potential mechanism needs further
investigation to clarify whether B. fragilis can induce fibrosis
and may thereby directly contribute to the development or
persistence of strictures.
To study the relevance of B. fragilis virulence factors, we
next compared the prevalence and relative abundance of bft
and ubb positive strains. Bft and Ubb are two B. fragilis
proteins, which have previously been shown to affect the
host via direct and indirect interactions, respectively (Wu
et al., 1998; Stewart et al., 2018). The metalloprotease Bft has
been shown to disrupt the epithelial barrier by cleaving
TABLE 2 | Distinctive B. fragilis coding sequences.
Predicted/hypothetical protein Length (aminoacids)
Fragilysin precursor (bftP_1) 406
Fragilysin precursor (bftP_2) 397
Transposase/IS protein 281
Transposase 507





the adherens junctions protein E-cadherin in vitro (Wu
et al., 1998), whereas Ubb was found to mimic human
Ubb and led to antibody formation in vivo (Stewart et al.,
2018). These two compounds were therefore considered of
interest and detected in the fecal metagenomes of CD
patients.
In our cohort, no difference was found in virulence factor
positive B. fragilis strains when comparing active and remissive
CD. Further analyses on associations between virulence factor
carriage and CD related parameters were not conclusive due to
the overall low prevalence. Although previous rather small scale
studies on bft in CD patients could also not demonstrate a link
with disease exacerbations (Prindiville et al., 2000; Zitomersky
et al., 2013) and studies on ubb among CD patients are lacking,
their gene products might still play a role in intestinal barrier
dysfunction and thereby contribute to intestinal inflammation.
We therefore subsequently investigated representative bacterial
strains for their effect on intestinal epithelial barrier function
using a validated Caco-2 barrier function model (Srinivasan
et al., 2015). To investigate the functional impact, we chose to
apply bacterial culture supernatant as it contains all secreted
products, including proteins, metabolites and MVs (Kaparakis-
Liaskos and Ferrero, 2015; Sicard et al., 2017; Parker et al., 2018).
In vivo, these products can interact with the host by directly
targeting the epithelial lining or indirectly via the immune
system (Kaparakis-Liaskos and Ferrero, 2015; Parker et al., 2018;
Badi et al., 2019).
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FIGURE 5 | NMR profiles of B. fragilis supernatant can distinguish between TEER-enhancing and non-TEER-enhancing strains. (A) The NMR spectra of all strains
are largely comparable. Acetate (*) and lactate (**) is relatively decreased in the TEER-enhancing B. fragilis strains HC-1, CD-1, and CD-3 compared to all other
strains. (B) PLS-DA plot demonstrates that the TEER-enhancing group (green) can be clearly discriminated from the non-TEER-enhancing (red) group.
In contrast to our hypothesis, none of the investigated
supernatants led to a disrupted epithelial barrier when examined
with TEER analysis. On the contrary, bft-positive culture
supernatant significantly increased epithelial barrier resistance.
The observed TEER increase was comparable for both, bft-1-
and bft-2-positive isotypes, which include the most prevalent
isotypes in the human gut (Sears, 2009). Even in the presence
of the inflammatory cytokines TNF-α and IFN-γ, which are
known to disrupt tight junctions (Eeckhaut et al., 2013;
Sturgeon and Fasano, 2016), bft-positive culture supernatant
evoked an equivalent TEER increase. As previous studies
have described a barrier disrupting effect induced by Bft in
some other colonic (adeno)carcinoma cell lines, such as HT-
29 or T84 (Chambers et al., 1997; Obiso et al., 1997), but
not in others, for instance Caco-2, NCI-H508 and LS174T
(Van Tassell et al., 1992), we also tested the effect of bft-
positive culture supernatant on a more physiological CD
patient-derived colonic organoid model of epithelial barrier
function (Xu et al., 2018). This likely confirmed that exposure
to bft-positive and bft-negative B. fragilis culture supernatant
did not lead to barrier disruption or any conspicuous
morphological changes, such as cell rounding, although it
remains possible that organoids from different hosts might
respond differently.
To further elucidate mechanisms underlying the pronounced
TEER elevation, junctional gene expression was examined. The
qPCR-based approach showed that altered gene expression
levels of junctional proteins are unlikely to contribute to the
TEER elevation evoked by Bft-positive culture supernatant.
Furthermore, induction of proliferation via the previously
described Bft-induced upregulation of the proto-oncogene c-
myc (Wu et al., 2003) was found to be unlikely. Other cellular
mechanisms might rather be involved in the detected TEER
increase, such as alterations in ion flux or post-translational
modifications of junctional proteins (Srinivasan et al., 2015;
Shigetomi and Ikenouchi, 2018). We further excluded a medium-
based effect, since the bacterial culture medium was the same for
all strains and was also used in the negative control.
Altogether, the above findings are not in line with previous
research on the mechanisms of Bft. Several studies showed that
isolated Bft could significantly decrease TEER via the cleavage
of the adherens junction protein E-cadherin (Wells et al., 1996;
Chambers et al., 1997; Obiso et al., 1997; Wu et al., 1998).
In those studies, Bft was purified and titrated to approximate
physiological concentrations (Van Tassell et al., 1992; Wells et al.,
1996; Chambers et al., 1997; Obiso et al., 1997; Wu et al., 1998).
In the present study, we chose to apply the complete culture
supernatant of 24 h bacterial cultures instead of purified Bft, to
include other secreted molecules and mimic a more physiological
situation. Although we succeeded to detect secreted Bft in the
supernatant, using a previously established HT-29 cell rounding
assay (Weikel et al., 1992), Bft concentrations were below the
detection limit of western blot. Furthermore, for barrier function
analysis Caco-2 cells were used instead of HT-29 or T84 cells,
which might vary in Bft susceptibility (Van Tassell et al., 1992;
Chambers et al., 1997; Obiso et al., 1997).
Next to a lack of epithelial barrier disruption in our Caco-
2 model, we showed that bft-positive culture supernatant also
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did not disrupt the epithelial barrier in more physiological,
human colonic organoids as mentioned above. This suggests
that our findings are not merely the result of a potentially more
resistant Caco-2 phenotype. However, as it has been previously
described that the response to Bft differs between cell lines,
we cannot completely rule out that the lack of response in
both, the Caco-2 model and human colonic organoids from a
CD patient, might be because of a more resistant phenotype.
Based on the previously reported E-cadherin cleavage and
subsequent barrier disruption (Obiso et al., 1997; Wu et al.,
1998), it seemed rather unlikely that Bft is contributing to the
observed increased TEER values in Caco-2 monolayers. We
could exclude Bft as causing factor, using additional bft-1- and
bft-2-positive reference strains with their respective bft-deletion
mutants. Both, wild type and mutants-derived supernatants
showed similar TEER elevation as observed in the original bft-
positive strains. Therefore, further research was conducted on
identifying the potential factor that might induce the observed
TEER elevation. As part of the bacterial secretome, B. fragilis
MVs were isolated from the supernatant and applied on the
Caco-2 monolayers. Since TEER values did not change after
24 h incubation, MVs were excluded as TEER elevating factors.
Next, whole genome sequencing was applied to identify strain
specific coding sequences, indicating differences in potentially
secreted proteins. The predicted proteins were related to the
pathogenicity island, including bft and metalloprotease II (mpII),
the transposon machinery, including transposase like protein and
putative transposase/insertion sequence protein, and a putative
amidoligase was predicted. So far, there is no reported evidence
on interaction with amidoligases and tight or adherens junctions.
Considering the related functions of the other predicted proteins,
they seem rather unlikely to induce TEER elevation, except
for MPII, which has earlier been shown to bind to E-cadherin
(Remacle et al., 2014). Since the close phylogeny of one TEER-
elevating and one non-TEER-elevating strain combined with our
observed TEER elevation in the bft deletion mutants offer limited
possibilities for the involvement of other genes, we hypothesize
that MPII likely contributed to the TEER elevation. Finally,
relative concentrations of acetate and lactate were lower in TEER-
increasing strains. However, short chain fatty acids, including
acetate, and lactate are reported to rather strengthen the epithelial
barrier (Bruininx et al., 2010; Zheng et al., 2017). The lower
acetate and lactate concentrations found in the supernatant of
TEER-enhancing strains are therefore unlikely to explain the
TEER-enhancing effect. Altogether, we could not elucidate the
mechanism underlying the significant increase in TEER by bft-
positive B. fragilis strains.
Besides the effect of Bft-containing supernatant, we further
evaluated the impact of ubb-positive strains. As mentioned above,
we could not observe epithelial disruption in this condition.
So far, little is known about the pathophysiological impact of
Ubb, but it has been associated with chronic auto-immune
diseases, including ulcerative colitis (Stewart et al., 2018). Since
we could not find an impact on barrier function, future
studies should focus on the interaction of Ubb with other
pathophysiological factors, especially pro-inflammatory immune
mediators, in Crohn’s disease. A combined clinical and in vitro
study could explore the presence of anti-Ubb antibodies in CD
patients and the subsequent immune response.
In summary, this study shows a higher B. fragilis, but not
bft or ubb, prevalence in CD exacerbations and an association
with a stricturing disease course. Surprisingly, the direct effect of
B. fragilis products on colonic epithelial cells led to a significant
TEER increase in bft-positive strains, which might indicate a
barrier stabilizing effect. This was, however, not due to Bft. More
detailed pathophysiological mechanisms and a potential clinical
relevance need further investigation. Additionally, this study
clearly stresses the need to investigate functional host-microbe
interactions to pursue on taxonomic and functional associations
based on microbiome research.
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